	US 11,732,020 B2
	T cell receptors and uses thereof
Christian Ellinger, Munich (DE); Carina Wehner, Munich (DE); Manon Weis, Sankt Wolfgang (DE); Susanne Wilde, Germering (DE); and Dolores Schendel, Munich (DE)
Assigned to MEDIGENE IMMUNOTHERAPIES GMBH, Planegg-Martinsried (DE)
Appl. No. 16/309,902
Filed by MEDIGENE IMMUNOTHERAPIES GMBH, Planegg-Martinsried (DE)
PCT Filed Jun. 16, 2017, PCT No. PCT/EP2017/064729 § 371(c)(1), (2) Date Dec. 13, 2018, PCT Pub. No. WO2017/216324, PCT Pub. Date Dec. 21, 2017.
Claims priority of application No. 93112 (LU), filed on Jun. 17, 2016; and application No. 17160260 (EP), filed on Mar. 10, 2017.
Prior Publication US 2019/0169261 A1, Jun. 6, 2019
Int. Cl. C07K 14/725 (2006.01); C07K 14/735 (2006.01); C07K 14/74 (2006.01); C07K 16/30 (2006.01); C07K 14/47 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61K 35/17 (2015.01)

CPC C07K 14/7051 (2013.01) [A61K 35/17 (2013.01); A61K 39/00119 (2018.08); A61P 35/00 (2018.01); C07K 14/4748 (2013.01); C07K 14/70539 (2013.01); C07K 16/3053 (2013.01); A61K 2039/5154 (2013.01); C07K 2317/34 (2013.01); C07K 2317/73 (2013.01)]

13 Claims

1. A T-cell receptor (TCR) comprising:

(i) a CDR alpha chain comprising a variable region having a CDR1 consisting of the amino acid sequence VSGLRG (SEQ ID NO: 5), a CDR2 consisting of the amino acid sequence of LYSAGEE (SEQ ID NO: 3), and a CDR3 consisting of the amino acid sequence of CAVHSTAQAGTALIF (SEQ ID NO: 1); and

(ii) a CDR beta chain comprising a variable region having a CDR1 consisting of the amino acid sequence of SGDLS (SEQ ID NO. 6), a CDR2 consisting of the amino acid sequence YYNGEE (SEQ ID NO. 4), and a CDR3 consisting of the amino acid sequence of CASSTHRGQTNYGYTF (SEQ ID NO. 2),

said TCR being capable of binding to the epitope comprised within the amino acid A sequence of VLDGLDVLL (SEQ ID NO:32) in its HLA-A*02:01-bound form.